Table 1.

Results of univariate analyses in liver cancer

Variables	No. of pat.	OS
		No. of event	MST	Χ 2	P
Gender
M	57	38	34.379	1.362	0.243
F	18	13	49.279
HBV
Yes	47	31	50.225	0.955	0.328
No	28	20	37.103
AFP
Normal	41	27	46.332	0.167	0.683
Elevated	28	21	43.324
NA
CA199
Normal	38	24	49.987	8.404	0.004
Elevated	23	20	25.283
NA
Histology
HCC	32	20	61.16	39.516	0.009
ICC	28	21	32.858
CHC	15	10	29.038
Size
<5 cm	43	29	51.091	1.095	0.295
>5 cm	32	22	40.582
Number
1	52	32	51.091	1.095	0.295
>2	23	19	37.885
Differentation
High	11	5	65.519	2.642	0.104
Low/modreate	53	38	44.269
Vascular invasion
Yes	9	7	36.820	0.778	0.378
No	66	44	46.773
Margin
Positive	15	13	51.995	7.732	0.005
Negative	60	38	23.267
TACE
Yes	44	31	45.507	0.073	0.788
No	31	20	47.191
Hepatocyte
Positive	39	25	54.548	3.711	0.054
Negative	36	26	35.337
GPC3
Positive	32	23	45.197	0.104	0.747
Negative	43	28	47.373
Hepatocyte/GPC3
Positive	47	30	52.426	2.918	0.088
Negative	28	21	34.572
CK7
Positive	43	29	39.425	2.3	0.129
Negative	22	22	54.523
CK19
Positive	42	28	35.361	4.698	0.030
Negative	33	23	56.665
CK7/CK19
Positive	49	33	39.721	2.670	0.102
Negative	26	18	56.772
EpCAM
Positive	39	24	36.206	4.841	0.028
Negative	36	27	56.132

No. of pat. number of patient; OS, overall survival; MST, mean survival time; TACE, transcatheter arterial chemoembolization